Verfahren zur Inaktivierung von Viren in Plasma und Plasmaderivaten — gegenwärtiger Kenntnisstand und künftige Entwicklungen

[1]  Laurence Corash,et al.  Use of 8-methoxypsoralen and long-wavelength ultraviolet radiation for decontamination of platelet concentrates , 1989, Photonics West - Lasers and Applications in Science and Engineering.

[2]  J. Belleroche,et al.  Glycine and neurodegenerative disease , 1991, The Lancet.

[3]  D. Economides,et al.  Parvovirus B19 infection and transient fetal hydrops , 1991, The Lancet.

[4]  R. Schiff,et al.  Prospective Study on the Hepatitis Safety of Intravenous Immunoglobulin, pH 4.25 , 1991, Vox sanguinis.

[5]  N. Geacintov,et al.  Inactivation of viruses in blood with aluminum phthalocyanine derivatives , 1991, Transfusion.

[6]  M. Tersmette,et al.  Inactivation of human immunodeficiency virus by gamma radiation and its effect on plasma and coagulation factors , 1991, Transfusion.

[7]  M. Blajchman,et al.  Blood product-associated bacterial sepsis. , 1991, Transfusion medicine reviews.

[8]  J. Preiksaitis.  Indications for the use of cytomegalovirus-seronegative blood products. , 1991, Transfusion medicine reviews.

[9]  S. Wagner,et al.  Approaches to the reduction of viral infectivity in cellular blood components and single donor plasma. , 1991, Transfusion medicine reviews.

[10]  J. Oldenburg,et al.  Acute HIV-1 Infection in Patients with Hemophilia B Treated with β-Propiolactone-UV-lnactivated Clotting Factor , 1990, Thrombosis and Haemostasis.

[11]  P. Mannucci,et al.  Antibody to hepatitis C virus after a vapour-heated factor VIII concentrate. The Study Group of the Fondazione dell'Emofilia. , 1990, Thrombosis and haemostasis.

[12]  D. Aronson.  The development of the technology and capacity for the production of factor VIII for the treatment of hemophilia A , 1990, Transfusion.

[13]  C. Pegelow,et al.  Transmission of Human Immunodeficiency Virus Type 1 by Dry‐Heated Clotting Factor Concentrates 1 , 1990, Vox sanguinis.

[14]  R. Purcell,et al.  Interrelationship of blood transfusion, non‐A, non‐B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus , 1990, Hepatology.

[15]  A. Prince,et al.  The use of tri(n‐butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation , 1990, Transfusion.

[16]  J. Fratantoni,et al.  Viral inactivation of blood products , 1990, Transfusion.

[17]  J. Levy,et al.  Development of a model to demonstrate photosensitizer‐mediated viral inactivation in blood , 1990, Transfusion.

[18]  A. Widell,et al.  Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate , 1990, The Lancet.

[19]  M. Oleggini,et al.  Ultraviolet irradiation of platelet concentrates: feasibility in transfusion practice , 1990, Transfusion.

[20]  William D. Dupont,et al.  Power and sample size calculations. A review and computer program. , 1990, Controlled clinical trials.

[21]  J. Lusher,et al.  Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. The Monoclate Study Group. , 1990, Seminars in hematology.

[22]  D. Piszkiewicz,et al.  Inactivation of HIV‐2 by solvent/detergent treatment , 1990, Transfusion.

[23]  M. Morfini,et al.  Virus inactivation in clotting factor concentrates: Facts and fancies , 1990 .

[24]  D. Rubinstein,et al.  Thermal Inactivation by Sequential Dry‐Heat Treatments at Sterilizing Temperatures (100°C‐Boiling) of Factor VIII and Factor IX Concentrates to Produce Sterile Concentrates , 1989 .

[25]  L. Sherman,et al.  Research opportunities in transfusion medicine. Report from an American Association of Blood Banks Think Tank , 1989 .

[26]  R. Straight,et al.  INACTIVATION AND MUTAGENESIS OF Herpes VIRUS BY PHOTODYNAMIC TREATMENT WITH THERAPEUTIC DYES , 1989, Photochemistry and photobiology.

[27]  D. Piszkiewicz,et al.  Inactivation and removal of human immunodeficiency virus in monoclonal purified antihemophilic factor (human) (Hemofil M). , 1989, Thrombosis research.

[28]  D. Evans,et al.  Severely Heated Therapeutic Factor VIII Concentrate of High Specific Activity , 1989, Vox sanguinis.

[29]  S. Urbaniak,et al.  Transmission of Non‐A, Non‐B Hepatitis by pH4‐Treated Intravenous Immunoglobulin , 1989, Vox sanguinis.

[30]  T. Suyama,et al.  Immunoglobulin Preparation: Safe from Virus Transmission? , 1989, Vox sanguinis.

[31]  P. Mannucci,et al.  Revision of the Protocol Recommended for Studies of Safety from Hepatitis of Clotting Factor Concentrates , 1989, Thrombosis and Haemostasis.

[32]  Deeg Hj.  Transfusions with a tan. Prevention of allosensitization by ultraviolet irradiation. , 1989 .

[33]  F. Claas,et al.  UV‐irradiated platelets: Ready to use? , 1989, Transfusion.

[34]  D. Brettler,et al.  Factor concentrates for treatment of hemophilia: which one to choose? , 1989, Blood.

[35]  A. Zuckerman,et al.  Effect of Gamma Irradiation on the Human Immunodeficiency Virus and Human Coagulation Proteins , 1989, Vox sanguinis.

[36]  F. Sieber,et al.  Mutagenicity of merocyanine 540-mediated photosensitization. , 1989, Experimental hematology.

[37]  J. Mcdougal,et al.  Heat inactivation of human immunodeficiency virus in solutions of antithrombin III , 1989, Transfusion.

[38]  B. Horowitz,et al.  Investigations into the application of tri(n-butyl)phosphate/detergent mixtures to blood derivatives. , 1989, Current studies in hematology and blood transfusion.

[39]  J. Hilfenhaus,et al.  Heat inactivation of human immunodeficiency virus type 2 (HIV-2). , 1989, Journal of biological standardization.

[40]  J. Morgenthaler.  Virus inactivation in plasma products. , 1989, Current studies in hematology and blood transfusion.

[41]  S. Sharkis,et al.  Inactivation of Friend erythroleukemia virus and Friend virus-transformed cells by merocyanine 540-mediated photosensitization. , 1989, Blood.

[42]  L. Corash,et al.  PHOTOCHEMICAL DECONTAMINATION OF BLOOD COMPONENTS CONTAINING HEPATITIS B AND NON-A, NON-B VIRUS , 1988, The Lancet.

[43]  D. Williams,et al.  Interleukin-1 alpha enhances the in vitro survival of purified murine granulocyte-macrophage progenitor cells in the absence of colony-stimulating factors. , 1988, Blood.

[44]  H. Brackmann,et al.  ACUTE HEPATITIS B INFECTION AFTER TREATMENT WITH HEAT-INACTIVATED FACTOR VIII CONCENTRATE , 1988, The Lancet.

[45]  P. Mannucci,et al.  VIRUCIDAL TREATMENT OF CLOTTING FACTOR CONCENTRATES , 1988, The Lancet.

[46]  J. Hudson,et al.  ANTIVIRAL PROPERTIES OF PHOTOSENSITIZERS * , 1988, Photochemistry and photobiology.

[47]  M. Hilgartner,et al.  VIRUS SAFETY OF SOLVENT/DETERGENT-TREATED ANTIHAEMOPHILIC FACTOR CONCENTRATE , 1988, The Lancet.

[48]  P. Agre,et al.  With Elliptocytosis and Rh Type in Three White Families , 1988 .

[49]  A. Zanetti,et al.  Prospective study of hepatitis after factor VIII concentrate exposed to hot vapour , 1988, British journal of haematology.

[50]  K. McGrath,et al.  Effect of virucidal heat treatment on proteins in human factor VIII concentrates , 1988, Transfusion.

[51]  J. Fratantoni,et al.  Inactivation of virus in blood products , 1988, Transfusion.

[52]  J. Newman,et al.  Photodynamic therapy of viral contaminants with potential for blood banking applications , 1988, Transfusion.

[53]  A. Prince,et al.  Inactivation of Lipid‐Enveloped Viruses in Labile Blood Derivatives by Unsaturated Fatty Acids , 1988, Vox sanguinis.

[54]  Q. Sattentau,et al.  PRELIMINARY EVALUATION OF PHTHALOCYANINE PHOTOSENSITIZATION FOR INACTIVATION OF VIRAL PATHOGENS IN BLOOD PRODUCTS , 1988 .

[55]  W. Stephan.  Virusinaktivierung in Blutprodukten , 1988 .

[56]  R. Emmons.  Ecology of Colorado tick fever. , 1988, Annual review of microbiology.

[57]  C. Cunningham-Rundles,et al.  Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. , 1988, The American journal of medicine.

[58]  M. Morfini,et al.  Ways to reduce the risk of transmission of viral infections by plasma and plasma products. A comparison of methods, their advantages and disadvantages. , 1988, Vox sanguinis.

[59]  T. Zuck.  Greetings—a final look back with comments about a policy of a zero‐ risk blood supply , 1987, Transfusion.

[60]  S. Sharkis,et al.  ANTIVIRAL ACTIVITY OF MEROCYANINE 540 , 1987, Photochemistry and photobiology.

[61]  J. Fratantoni,et al.  Use of laser-UV for inactivation of virus in blood products. , 1987, Blood.

[62]  G. Norkrans.  Post-transfusion non-A, non-B hepatitis. , 1987, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy.

[63]  J. van der Zee,et al.  The influence of ozone on human red blood cells. Comparison with other mechanisms of oxidative stress. , 1987, Biochimica et biophysica acta.

[64]  P. Mannucci,et al.  Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions. , 1987, The New England journal of medicine.

[65]  J. Vaughn,et al.  Inactivation of human and simian rotaviruses by ozone , 1986, Applied and environmental microbiology.

[66]  O. Weiland,et al.  NON-A, NON-B HEPATITIS AFTER INTRAVENOUS GAMMAGLOBULIN , 1986, The Lancet.

[67]  M. Wiebe,et al.  Inactivation of viruses in labile blood derivatives. I. Disruption of lipid‐enveloped viruses by tri(n‐butyl)phosphate detergent combinations , 1985, Transfusion.

[68]  P. Mannucci,et al.  TRANSMISSION OF NON-A, NON-B HEPATITIS BY HEAT-TREATED FACTOR VIII CONCENTRATE , 1985, The Lancet.

[69]  H. Kingdon,et al.  NON-A, NON-B HEPATITIS AND INTRAVENOUS IMMUNOGLOBULIN , 1985, The Lancet.

[70]  J. Spivak,et al.  Selective killing of leukemic cells by merocyanine 540-mediated photosensitization. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[71]  H. Thomas,et al.  NON-A, NON-B HEPATITIS OCCURRING IN AGAMMAGLOBULINAEMIC PATIENTS AFTER INTRAVENOUS IMMUNOGLOBULIN , 1984, The Lancet.

[72]  H. Oberman,et al.  Transfusion of plasma components , 1984, Transfusion.

[73]  R. Lane,et al.  NON-A, NON-B HEPATITIS FROM INTRAVENOUS IMMUNOGLOBULIN , 1983, The Lancet.

[74]  D. Bradley,et al.  Posttransfusion Non-A, Non-B Hepatitis: Physicochemical Properties of Two Distinct Agents , 1983, The Journal of infectious diseases.

[75]  E. Farber,et al.  Long-term risks of psoralen and UV-A therapy for psoriasis. , 1983, Archives of dermatology.

[76]  E. H. Lennette,et al.  The development of Colorado tick fever virus within cells of the haemopoietic system. , 1978, The Journal of general virology.

[77]  J. Hearst,et al.  Psoralen-DNA photoreaction: controlled production of mono- and diadducts with nanosecond ultraviolet laser pulses. , 1977, Science.

[78]  S. Person,et al.  Inactivation of Lipid-Containing Viruses by Long-Chain Alcohols , 1977, Antimicrobial Agents and Chemotherapy.

[79]  E. Katzenelson,et al.  Inactivation Kinetics of Viruses and Bacteria in Water by Use of Ozone , 1974 .

[80]  Rodan Ks.  Letter: The consultants' contract. , 1974, Lancet.

[81]  P. Mollison.  Blood transfusion in clinical medicine , 1967 .

[82]  J. R. Perdrau,et al.  The Photodynamic Action of Methylene Blue on Certain Viruses , 1933 .

[83]  C. E. Clifton.  Photodynamic Action of Certain Dyes on the Inactivation of Staphylococcus Bacteriophage. , 1931 .